Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577837 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
A Phase 2 study of Postmenopausal, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 370
- Enrollment target
- 14
- Study locations
NCT00577837: Completed Phase 2 study of Postmenopausal, sponsored by Warner Chilcott.
NCT00577837 is a Phase 2 study of Postmenopausal that has completed, run by Warner Chilcott. The registered enrollment target is 370 participants, above the 100-participant average among 9 other Postmenopausal trials with a reported enrollment target (270% higher). The trial reports 14 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00577837, a Phase 2 study of Postmenopausal, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 370 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Multi-center, Active-controlled (5 mg daily risedronate), Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly for Six Months in Postmenopausal Women with Low Bone Mineral Density.
Conditions Studied
Interventions
- DRUG risedronate
- DRUG experimental
Study Locations (14)
Other
- Research Facility - Zagreb
- Research Facility - Amsterdam
- Research Facility - Leiden
- Research Facility - Bialystok
- Research Site - Lublin
- Research Site - Warsaw
- Research Site - Wroclaw
Florida
- Research Site - Daytona Beach
- Research Site - Gainesville
Quebec
- Research Facility - Montreal
- Research Facility - Sainte-Foy
Kansas
- Research Site - Shawnee Mission
Texas
- Research Site - San Antonio
Ontario
- Research Site - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00577837 record still lists
NCT00577837 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, above the 100-participant average among 9 other Postmenopausal trials with a reported enrollment target (270% higher).
The record links to 1 condition, with Postmenopausal appearing as the primary indexed condition, and to 2 interventions - of which risedronate is the first listed.
NCT00577837 lists 14 locations in 6 states (Other, Florida, Quebec).
Frequently Asked Questions
What is clinical trial NCT00577837 about?
NCT00577837 is a clinical study titled "Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD". A Multi-center, Active-controlled (5 mg daily risedronate), Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly for Six Months in Postmenopausal Women with Low Bone Mineral Density.
What is the current status of trial NCT00577837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 370 participants. The study started on 2004-04. Estimated completion is 2005-06.
What conditions does trial NCT00577837 study?
This clinical trial studies the following conditions: Postmenopausal.
What interventions are being tested in trial NCT00577837?
The interventions under investigation include: risedronate (DRUG), experimental (DRUG).
Who is sponsoring clinical trial NCT00577837?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00577837 being conducted?
This trial has 14 study locations across Florida, Kansas, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00577837's enrollment target sits among peer trials
370 1st of 9 higher than 9 of 9 other Postmenopausal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postmenopausal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
COMPLETED · Phase 2
-
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
COMPLETED · Phase 2
-
Protein and Exercise for Postmenopausal Women's Wellbeing
RECRUITING · NA
-
Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women
RECRUITING · NA
-
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
COMPLETED · NA
-
Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia